SRS Capital Advisors Inc. Buys 4,324 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

SRS Capital Advisors Inc. boosted its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 817.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,853 shares of the company’s stock after buying an additional 4,324 shares during the quarter. SRS Capital Advisors Inc.’s holdings in 10x Genomics were worth $70,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in TXG. Capital Performance Advisors LLP acquired a new position in shares of 10x Genomics in the third quarter worth approximately $35,000. Venturi Wealth Management LLC boosted its stake in shares of 10x Genomics by 1,108.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock valued at $55,000 after purchasing an additional 2,240 shares during the last quarter. First Horizon Advisors Inc. increased its position in shares of 10x Genomics by 53.3% during the third quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock worth $66,000 after buying an additional 1,012 shares during the period. Blue Trust Inc. raised its stake in 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock worth $44,000 after buying an additional 1,299 shares during the last quarter. Finally, KBC Group NV lifted its holdings in 10x Genomics by 38.8% in the third quarter. KBC Group NV now owns 3,225 shares of the company’s stock valued at $73,000 after buying an additional 902 shares during the period. Institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

NASDAQ:TXG opened at $11.47 on Friday. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -7.55 and a beta of 1.93. The stock has a fifty day moving average of $13.68 and a 200 day moving average of $16.51. 10x Genomics, Inc. has a 52-week low of $9.27 and a 52-week high of $42.85.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Equities analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Leerink Partners downgraded 10x Genomics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $25.00 to $12.00 in a report on Thursday, February 13th. Morgan Stanley cut their price target on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. JPMorgan Chase & Co. dropped their target price on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Barclays decreased their target price on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Finally, Stifel Nicolaus reduced their price target on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, 10x Genomics has a consensus rating of “Hold” and a consensus price target of $20.21.

Insider Buying and Selling

In other 10x Genomics news, Director Alan Mateo purchased 40,000 shares of the business’s stock in a transaction on Friday, February 21st. The stock was acquired at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the transaction, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. This represents a 184.41 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the transaction, the insider now owns 335,324 shares in the company, valued at approximately $3,712,036.68. This represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. 10.03% of the stock is owned by company insiders.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.